334970 — Prestige Biologics Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Prestige Biologics Co, fiscal year end - June 30th, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 June 30th	2024 June 30th
Period Length:	12 M	12 M	12 M	6 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-31,033	-39,378	-49,718	-17,980	-29,374
Depreciation
Amortisation
Non-Cash Items	15,727	32,453	19,835	11,157	-9,771
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-1,126	-22,865	-12,245	-1,870	19,569
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-13,330	-25,869	-34,190	-4,450	-8,345
Capital Expenditures	-3,051	-98,011	-84,790	-19,495	-8,637
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	10,211	101	1,124	18.2	711
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	7,160	-97,910	-83,665	-19,477	-7,927
Financing Cash Flow Items	—	-28.4	-42.7	—	-52.3
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-1,179	156,312	96,463	53,979	345
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-7,350	32,533	-21,392	30,052	-15,928